A detailed history of Geode Capital Management, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,008,214 shares of CRSP stock, worth $47.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,008,214
Previous 973,018 3.62%
Holding current value
$47.6 Million
Previous $52.6 Million 9.85%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$44.62 - $62.75 $1.57 Million - $2.21 Million
35,196 Added 3.62%
1,008,214 $47.4 Million
Q2 2024

Aug 09, 2024

BUY
$51.17 - $68.18 $3.26 Million - $4.34 Million
63,720 Added 7.01%
973,018 $52.6 Million
Q1 2024

May 13, 2024

BUY
$60.67 - $89.12 $1.55 Million - $2.28 Million
25,569 Added 2.89%
909,298 $62 Million
Q4 2023

Feb 13, 2024

BUY
$38.62 - $72.18 $1.31 Million - $2.44 Million
33,791 Added 3.98%
883,729 $55.3 Million
Q3 2023

Nov 13, 2023

BUY
$45.39 - $59.0 $695,874 - $904,529
15,331 Added 1.84%
849,938 $38.6 Million
Q2 2023

Aug 11, 2023

BUY
$43.47 - $67.77 $1.07 Million - $1.67 Million
24,623 Added 3.04%
834,607 $46.9 Million
Q1 2023

May 15, 2023

BUY
$41.0 - $56.12 $856,326 - $1.17 Million
20,886 Added 2.65%
809,984 $36.6 Million
Q4 2022

Feb 13, 2023

BUY
$39.19 - $65.67 $957,098 - $1.6 Million
24,422 Added 3.19%
789,098 $32.1 Million
Q3 2022

Nov 14, 2022

BUY
$61.1 - $83.78 $3.08 Million - $4.23 Million
50,481 Added 7.07%
764,676 $50 Million
Q2 2022

Aug 12, 2022

BUY
$43.23 - $73.83 $2.21 Million - $3.77 Million
51,106 Added 7.71%
714,195 $43.4 Million
Q1 2022

May 13, 2022

BUY
$53.19 - $79.24 $31.7 Million - $47.3 Million
596,823 Added 900.65%
663,089 $41.6 Million
Q4 2021

Feb 11, 2022

BUY
$70.09 - $111.29 $126,932 - $201,546
1,811 Added 2.81%
66,266 $5.02 Million
Q3 2021

Nov 12, 2021

BUY
$110.2 - $156.64 $66,120 - $93,983
600 Added 0.94%
64,455 $7.21 Million
Q2 2021

Aug 13, 2021

SELL
$100.84 - $161.89 $18,252 - $29,302
-181 Reduced 0.28%
63,855 $10.3 Million
Q1 2021

May 12, 2021

BUY
$110.72 - $210.04 $1.28 Million - $2.42 Million
11,536 Added 21.97%
64,036 $7.8 Million
Q4 2020

Feb 12, 2021

BUY
$79.67 - $173.23 $100,543 - $218,616
1,262 Added 2.46%
52,500 $8.04 Million
Q3 2020

Nov 13, 2020

BUY
$78.5 - $100.64 $301,361 - $386,356
3,839 Added 8.1%
51,238 $4.29 Million
Q2 2020

Aug 13, 2020

BUY
$38.5 - $76.05 $171,286 - $338,346
4,449 Added 10.36%
47,399 $3.48 Million
Q1 2020

May 14, 2020

BUY
$33.68 - $62.53 $125,154 - $232,361
3,716 Added 9.47%
42,950 $1.82 Million
Q4 2019

Feb 13, 2020

BUY
$36.68 - $73.13 $27,803 - $55,432
758 Added 1.97%
39,234 $2.39 Million
Q3 2019

Nov 12, 2019

SELL
$40.99 - $52.56 $9,181 - $11,773
-224 Reduced 0.58%
38,476 $1.58 Million
Q2 2019

Aug 14, 2019

BUY
$35.45 - $48.2 $3,970 - $5,398
112 Added 0.29%
38,700 $1.82 Million
Q1 2019

May 14, 2019

BUY
$28.02 - $40.87 $101,292 - $147,745
3,615 Added 10.34%
38,588 $1.38 Million
Q4 2018

Feb 13, 2019

SELL
$22.73 - $42.34 $19,365 - $36,073
-852 Reduced 2.38%
34,973 $999,000
Q3 2018

Nov 13, 2018

BUY
$44.35 - $65.71 $14,635 - $21,684
330 Added 0.93%
35,825 $1.59 Million
Q2 2018

Aug 14, 2018

BUY
$42.62 - $73.59 $340,192 - $587,395
7,982 Added 29.01%
35,495 $2.09 Million
Q1 2018

May 15, 2018

BUY
$23.52 - $58.17 $12,348 - $30,539
525 Added 1.95%
27,513 $1.26 Million
Q4 2017

Feb 13, 2018

BUY
$16.95 - $23.48 $9,661 - $13,383
570 Added 2.16%
26,988 $633,000
Q3 2017

Nov 14, 2017

BUY
$16.75 - $20.66 $134,536 - $165,941
8,032 Added 43.69%
26,418 $472,000
Q2 2017

Aug 14, 2017

BUY
N/A
18,386
18,386 $294,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.69B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.